Do CNV Subtypes Matter for Prognosis, Diagnosis, and Treatment?

Program Overview

CNV Subtypes and Clinical Features

Identifying and Diagnosing Different CNV Subtypes

Treatment Options for CNV Subtypes

DRAGON Study Schema: Phase 4, 24-Month, Randomized, Double-Masked, Controlled, Multicenter Study

At Baseline, 41.7% of Patients Were Diagnosed With PCV

Ranibizumab Treatment Resulted in BCVA Improvements, Regardless of PCV Status

Number of Injections Administered Was Similar for Patients With PCV and non-PCV

LUMINOUS Trial: Mean VA Outcomes in Global Population: 1-Year Follow-Up Data

LUMINOUS Trial: Safety Outcomes in Global Population: 1-Year Follow-Up Data

EVEREST II: The Largest Multicenter RCT Conducted for PCV

EVEREST II: Treatment Schedule

BCVA Change From Baseline to Month 12 and Complete Polyp Regression at Month 12

Number of Injections Received in Study Eye Prior to Month 12

Number of vPDT/Sham PDT Received in the Study Eye Prior to Month 12

PLANET Study: Aflibercept Monotherapy vs Aflibercept Plus PDT in Patients With PCV

CATT Study: RAP Subgroup Analysis

Importance of Differentiating RAP Lesions

Concluding Remarks

Abbreviations

Abbreviations (cont)